4570 — Immuno-Biological Laboratories Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.95 | ||
| Price to Tang. Book | 4.95 | ||
| Price to Free Cashflow | 34.9 | ||
| Price to Sales | 8.65 | ||
| EV to EBITDA | 24.47 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 17.29% | ||
| Return on Equity | 21.27% | ||
| Operating Margin | 30.83% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 647.58 | 794.62 | 816.7 | 969.53 | 1,004.99 | n/a | n/a | 10.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +33.04 | +32.11 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immuno-Biological Laboratories Co., Ltd. is a Japan-based company engaged in the research, development, manufacture and sales of pharmaceutical products and quasi-drugs. The Company operates in four business segments. The Diagnostic and Reagent segment is engaged in the manufacture, purchase and sales of research-related reagents, medicine, as well as vitro diagnostics. The Genetically Modified Silkworm segment is engaged in the sales of transgenic silkworm cocoons related products and research development of pharmaceutical raw materials. The Testing segment is engaged in the provision of support for prevention and diagnosis in addition to drug discovery and research support in the field of lifestyle-related diseases using lipid metabolism analysis technology. The Cosmetics segment is engaged in the sales of cosmetics and other products.
Directors
- Tsutomu Seito PRE (68)
- Shoko Onodera DHR (60)
- Masato Nakagawa OTH (53)
- Masahiro Maeda OTH (63)
- Masahiro Tomita OTH (55)
- Kenji Fukunaga IND (51)
- Ikkei Kojima IND (38)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- September 9th, 1982
- Public Since
- March 2nd, 2007
- No. of Shareholders
- 13,864
- No. of Employees
- 54
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 9,313,458
- Address
- 1091-1, Naka Higashida, FUJIOKA-SHI, 375-0005
- Web
- https://www.ibl-japan.co.jp
- Phone
- +81 274222889
- Auditors
- Shinjuka Audit Corporation
Latest News for 4570
Upcoming Events for 4570
Q2 2027 Immuno-Biological Laboratories Co Ltd Earnings Release
Dividend For 4570.T - 7.5000 JPY
Similar to 4570
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 21:16 UTC, shares in Immuno-Biological Laboratories are trading at ¥1,003. This share price information is delayed by 15 minutes.
Shares in Immuno-Biological Laboratories last closed at ¥1,003 and the price had moved by +107.66% over the past 365 days. In terms of relative price strength the Immuno-Biological Laboratories share price has outperformed the Nikkei 225 Index by +61.12% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Immuno-Biological Laboratories dividend yield is 0.6% based on the trailing twelve month period.
Last year, Immuno-Biological Laboratories paid a total dividend of ¥6, and it currently has a trailing dividend yield of 0.6%. We do not have any data on when Immuno-Biological Laboratories is to next pay dividends.
We do not have data on when Immuno-Biological Laboratories is to next pay dividends. The historic dividend yield on Immuno-Biological Laboratories shares is currently 0.6%.
To buy shares in Immuno-Biological Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,003, shares in Immuno-Biological Laboratories had a market capitalisation of ¥9bn.
Here are the trading details for Immuno-Biological Laboratories:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4570
Based on an overall assessment of its quality, value and momentum Immuno-Biological Laboratories is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immuno-Biological Laboratories. Over the past six months, its share price has underperformed the Nikkei 225 Index by -30.72%.
As of the last closing price of ¥1,003, shares in Immuno-Biological Laboratories were trading -20.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Immuno-Biological Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥1,003.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Immuno-Biological Laboratories' management team is headed by:
- Tsutomu Seito - PRE
- Shoko Onodera - DHR
- Masato Nakagawa - OTH
- Masahiro Maeda - OTH
- Masahiro Tomita - OTH
- Kenji Fukunaga - IND
- Ikkei Kojima - IND